Olivia
Online
Diogo Assed Bastos
@DiogoAssed
Medical oncologist and clinical researcher focused on Genitourinary oncology at @hsiriolibanes
Sao Paulo, Brazil
Joined June 2018
336 Following
673 Followers
141 Posts
Star-studded international cast led by @Prof_Nick_James @APCCC_Lugano, addressing gaps in access to #cancer care. From diagnostic tools & treatments to education & clinical trials, regional differences exist - but the mission to close the gaps is universal. 🌎 @Silke_Gillessen @AOmlin @VedangMurthy @LoebStacy @ASCOPres @BrandonMahal
@DiogoAssed from 🇧🇷 wonderful presentation @APCCC_Lugano about drug repurposing & optimización in #prostatecancer
✅Low dose abiraterone
✅Low dose IO
✅Bi-polar androgen deprivation tx
Critican strategies in the era of high-cost tx‼️‼️‼️🌏
10 years of @APCCC_Lugano
So happy to be a panelist from 🇲🇽!! #prostatecancer 1st cause of cancer death in men in the country
More LATAM 🇧🇷🇦🇷 @DiogoAssed @jpsade2 @DrAndreFay @nataliagandur
@OncoAlert @oncodaily @Uromigos @aaoncoclinica
Coverage of #APCCC26 🇨🇭 by @OncoAlert 🚨 Day Two
How to ensure everyone gets the best possible care in different contexts? Drug repurposing and drug optimization. Presented by Dr. Diogo Added Bastos 🇧🇷
Drug repurposing and optimization are essential to expand access in advanced prostate cancer, especially in the context of rising drug costs. From bilateral orchiectomy to low-dose abiraterone, smarter use of existing therapies can reduce costs and maintain efficacy. We must prioritize clinical trials that focus not only on new drugs, but on better use of current treatments.
#ProstateCancer #ProstateCancer Week
@APCCC_Lugano
@Silke_Gillessen
@AOmlin
@weoncologists
@declangmurphy
@RenuEapen
@DrYukselUrun
@nataliagandur
@fabioturco92
@UrsulaVogl
@SScagliarini
@Tylersbrt
@neerajaiims
@amerseburger
@Cdanicas
@AarmstrongDuke
@BertrandTOMBAL
@ChrisSweens1
@EAntonarakis
@KOSJ12
@VedangMurthy
@DrRanaMcKay
@LoebStacy
@stefanofanti4
@mirrorsmed
@profkhermann
@dr_coops
@piet_ost
@_ShankarSiva
@DrSpratticus
@scocmem
@AmandaNizamMD
@tompowles1
@brian_rini
@Uromigos
@EUplatinum
@EANM_NucMed
@ESTRO_RT
@Uroweb
Who to follow
Denis Jardim
@jardim_denis
Chief of GU Cancer @oncoclinicas Scientific Director GU tumors @Lacog_group
Andrey Soares
@SoaresAndrey
Scientific Committee Member LACOG - GU | Medical Oncologist at Hospital Albert Einstein | Owner and founder BIO | Following or RT does not mean endorsement
Marcelo Corassa, MD. 
@MarceloCorassa
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology. Views are my own.
An amazing Day 2️⃣ of #APCCC26
Our thanks To our great Partners at APCCC
1️⃣ 9️⃣ Million Impressions and counting
A Great #ProstateCancerWeek in Lugano
#ProstateCancer
@APCCC_Lugano
@Silke_Gillessen
@AOmlin
@weoncologists
@declangmurphy
@RenuEapen
@DrYukselUrun
@nataliagandur
@fabioturco92
@UrsulaVogl
@SScagliarini
@Tylersbrt
@neerajaiims
@amerseburger
@Cdanicas
@AarmstrongDuke
@BertrandTOMBAL
@ChrisSweens1
@EAntonarakis
@KOSJ12
@VedangMurthy
@DrRanaMcKay
@LoebStacy
@stefanofanti4
@mirrorsmed
@profkhermann
@dr_coops
@piet_ost
@_ShankarSiva
@DrSpratticus
@scocmem
@AmandaNizamMD
@tompowles1
@brian_rini
@dmukherji
@Uromigos
@LoebStacy
@DrSpratticus
@BourlonMaite
@zklaassen_md
@Martin_AngelMD
@RodRogSan
Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇 https://t.co/d34qu62Ta3 The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore Eric Small Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul Consuelo Buttigliero Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono
@mdesantis234
@nachoduranm
Onyeanunam N. Ekeke Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis Susan Halabi Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship
Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji
@declangmurphy
Vedang Murthy Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura
@DrYukselUrun
Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero
@AOmlin
Ping @nataliagandur @bavilima @OncoAlert 🚨
No Better way to start 2025
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer
A Report from #APCCC24 LINK TO ARTICLE👇👇👇
https://t.co/QL8Kuyhxuj
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore Eric Small Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul Consuelo Buttigliero Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis Susan Halabi Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal Fernando C. Maluf ,
@quimmateo
David Matheson, Mika P. Matikainen , Ray McDermott,
@DrRanaMcKay
Niven Mehra,
@amerseburger
@CaPsurvivorship
Michael J. Morris , Hind Mrabti, Deborah Mukherji
@declangmurphy
Vedang Murthy Shingai B.A. Mutambirwa
@DrPaulNguyen
@WilliamOhMD
@piet_ost
Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemur
@DrYukselUrun
Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero
@AOmlin
In patients with localized #ProstateCancer who are clinically staged as T2 based on digital rectal examination cN0 cM0 and ISUP GG ≥3 carcinoma and clear evidence of T3 disease on MRI
Link:https://t.co/QL8Kuyhxuj
The consensus at @APCCC_Lugano 2024 was overwhelmingly in favor of treating as T3.
Of the panel, 9⃣6⃣% recommended adjusting treatment based on the MRI 🩻🧲findings, while only 4% supported sticking with the DRE-based T2 classification.
This highlights the growing reliance on MRI for more accurate staging in prostate cancer, especially when DRE results are limited or inconsistent.
When staging high-risk prostate cancer, next-generation imaging technologies such as whole-body MRI and PSMA PET/CT have become preferred due to their superior sensitivity and specificity compared to conventional methods like CT and bone scintigraphy. However, PSMA PET/CT is not without challenges, as it can produce false positives due to PSMA expression in non-cancerous tissues. In cases where PSMA PET detects bone lesions without corresponding findings on CT, 73% of APCCC 2022 panelists recommended further imaging or biopsy to verify the findings, with a similar recommendation at APCCC 2024. This cautious approach reflects the importance of thorough interpretation and corroboration in advanced imaging techniques.
Find out more on our publication published on @EUplatinum
Our Thanks to all authors (some tagged):
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@EfstathiouEleni
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@AOmlin
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24
LINK TO ARTICLE👇👇👇👇👇👇👇👇
https://t.co/QL8Kuyhxuj
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking.
The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting.
The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer.
Our Thanks to all authors:
@Silke_Gillessen
@fabioturco92
@Prof_IanD
@drjefstathiou
Karim Fizazi
@Prof_Nick_James
Neal Shore
Eric Small
Matthew Smith
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
Emmanuel S. Antonarakis
Ana Aparicio
Andrew J. Armstrong
Diogo Assed Bastos
Gerhardt Attard
Karol Axcrona
Mouna Ayadi
Himisha Beltran
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
Muhammad Bulbul
Consuelo Buttigliero
Orazio Caffo
@cdanicas
@Ecastromarcos
Heather H. Cheng
Kim N. Chi
Caroline S. Clarke
Noel Clarke
Johann S. de Bono
@mdesantis234
@nachoduranm
@EfstathiouEleni
Onyeanunam N. Ekeke
Tamer I.H. El Nahas
@drlouiseemmett
@stefanofanti4
Omolara A. Fatiregun
Felix Y. Feng
Peter C.C. Fong
@fontev1
@Nicola_Fossati
Daniel J. George
@marty_gleave
Gwenaelle Gravis
Susan Halabi
Daniel Heinrich
@ProfKHerrmann
@DrMHofman
Thomas A. Hope
Lisa G. Horvath
Maha H.A. Hussain
@BarbaraJereczek
Robert J. Jones
Anthony M. Joshua
@ravikanesvaran
Daniel Keizman
@FacsRaja
Gero Kramer
@LoebStacy
Brandon A. Mahal
Fernando C. Maluf 75 76,
@quimmateo
David Matheson 78,
Mika P. Matikainen 79,
Ray McDermott 80,
@DrRanaMcKay
Niven Mehra 82,
@amerseburger
@CaPsurvivorship ,
Michael J. Morris 85,
Hind Mrabti 86,
Deborah Mukherji
@declangmurphy
Vedang Murthy
Shingai B.A. Mutambirwa
@DrPaulNguyen
William K. Oh
@piet_ost
Joe M. O’Sullivan
Anwar R. Padhani
Chris Parker
Darren M.C. Poon
Colin C. Pritchard
Danny M Rabah
Dana Rathkopf
Robert E. Reiter
Raphaele Renard-Penna
Charles J. Ryan
Fred Saad
Juan Pablo Sade
Shahneen Sandhu
Oliver A. Sartor
Edward Schaeffer
Howard I. Scher
Nima Sharifi
Iwona A. Skoneczna
Howard R. Soule
@DrSpratticus
Sandy Srinivas
@cnsternberg
Hiroyoshi Suzuki
Mary-Ellen Taplin
Camilla Thellenberg-Karlsson
Derya Tilki
Levent N. Türkeri
Hiroji Uemura
@DrYukselUrun
Claire L. Vale
Neha Vapiwala
Jochen Walz
Kosj Yamoah
Dingwei Ye
Evan Y. Yu
Almudena Zapatero
@AOmlin
After Radicals-HD there is still a lot of questions about adding ADT to salvage Rtx
Join us for this multidisciplinary debate
👉07/10/24 ⏰7:30 pm (GMT-3)
Register online and free at https://t.co/ONZ2DauKS0
@RafaelFCoelho2 @DiogoAssed @fsabino_onco @mauzappa @docmeetings
Probably an outdated discussion, but our randomized trial Open versus RARP was finally published. A Herculean effort that started 10 years ago
Day 2 of #APCCC24 has wrapped, marking another fantastic chapter in advancing prostate cancer care.
We celebrate the wealth of knowledge exchanged and the consensus achieved on many pressing questions in advanced prostate cancer management.
🔬 Vital discussions have paved the way for advancements in treatment.
🌐 Knowledge transfer has been at the core, transcending boundaries.
🤝 Networking has connected us, fostering future collaborations.
Your active participation is also what makes #APCCC24 impactful around the globe:
🌟 21 Million Impressions
💬 Over 3.3K Tweets shared
Thanks again to @OncoAlert for the numbers provided 🤗
To all delegates, thank you for bringing your expertise and enthusiasm. Together, we're making strides in oncology.
#APCCC24 #ProstateCancer #ConsensusBuilding #GlobalOncology @Silke_Gillessen @AOmlin @urotoday @PCFnews
🌟 Be part of a pivotal moment in advanced #prostatecancer managment at #APCCC24!
Join global experts in consensus discussions that shape future treatments.
🗓️ Register now for an unmissable experience: https://t.co/eFBFJWiXha
#Oncology #GU24 #oncoalert
🌟 Be part of a pivotal moment in advanced #prostatecancer managment at #APCCC24!
Join global experts in consensus discussions that shape future treatments.
🗓️ Register now for an unmissable experience: https://t.co/eFBFJWiXha
#Oncology #GU24 #oncoalert
✨ The Advanced Prostate Cancer Consensus Conference (APCCC) 2024 is fast approaching, and we're thrilled to unveil our panel of esteemed global experts!
🌐 Meet the panel shaping the future of prostate cancer care! Join us at #APCCC24 for unparalleled insights and collaborative discussions. Don't miss out – register now!
🔗 Visit https://t.co/zkUcxACO1F for more information.
📆 25-27 April 2024
Save the date and be a part of the conversation that will shape the future of advanced prostate cancer management.
#APCCC24 #HealthcareConferences #Oncology #MedicalProfessionals #CancerResearch #ConsensusConference @Silke_Gillessen @AOmlin @OncoAlert
An amazing opportunity to learn about prostate cancer is APCCC 2024 in beautiful Lugano!
Register here https://t.co/7AZ4hjsKX8
@APCCC_Lugano @Silke_Gillessen @AOmlin @DanaFarber_GU
Prostate cancers with combined BRCA2 and SPOP mutations have greater homologous repair deficiency and increased sensitivity to PARP inhibitors. This is a clinically actionable patient subset! Congrats to our collaborators from 13 centers.
https://t.co/v36iqjDX77
2023 is almost over! A wrap-up of the most important and practice changing data in GU tumors (urology, medonc, radiology, rdt)
👉11/29/23 ⏰7:30 pm (GMT-3) @PublioViana @DiogoAssed @RafaelFCoelho2 @docmeetings @DocmeetingsOnco
https://t.co/ONZ2DaviHy -online and free
Join us for the GU highlights of #ESMO2023. Practical and important topics with great superstars discussing.
👉10/25/23 ⏰7:30 pm (GMT-3) @Felipegaliza @drdanielvargas
@DiogoAssed @RafaelFCoelho2 @docmeetings @DocmeetingsOnco
https://t.co/ONZ2DauKS0 -online and free
🚀 Elevate the Consenus at #APCCC24!
🌟 Engage, Debate, Shape Future Guidelines!
🔗 Meet the Panel & Join Us → https://t.co/jRlbQZOb5W
#ProstateCancer #Oncology #CancerResearch #MedicalConference #ClinicalConsensus #APCCC
Most Popular Users
Elon Musk
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.1M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
86.9M followers
Taylor Swift
@taylorswift13
80.7M followers
Lady Gaga
@ladygaga
72.3M followers
Kim Kardashian
@kimkardashian
69.4M followers
Virat Kohli
@imvkohli
68.7M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.5M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.2M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60M followers